Integrated therapeutic strategies for anaplastic thyroid carcinoma

Roberto Buzzoni¹, Laura Catena, Diego Cortinovis

¹UO Oncologia Medica B, National Cancer Institute, Milan, Italy.

|February 12, 2004

Abstract:

Anaplastic thyroid carcinoma (ATC) is a very rare neoplasm with an aggressive course. The prognosis has not changed in the last decades and the median survival does not exceed six months. Only few patients with incidental limited ATC will be cured. Different therapeutic options have been explored but the results are disappointing. At present, new drugs and new timing for proper treatment are under investigation. In this short review we have summarized these recent developments.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

The oncologist·2026

Immune-related adverse events from checkpoint inhibitors: An evidence-based management review.

Critical reviews in oncology/hematology·2026

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Cancer·2026

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

Nature cancer·2026

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.

Cancer discovery·2026

See all related articles

Related Experiment Videos

Integrated therapeutic strategies for anaplastic thyroid carcinoma

Related Concept Videos

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

Immune-related adverse events from checkpoint inhibitors: An evidence-based management review.

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.

Survival of carcinoid lung neuroendocrine tumours after surgical resection: A retrospective audit of 633 cases over 26 years.

Analysing workflows in radiation oncology: A process mining approach to identify treatment process challenges.

A radiomic approach to non-invasively decode tumor immune microenvironmental features in surgically resected non-small cell lung cancer.

When biological complexity demands more than better trial designs.

Chimeric thoracodorsal free flap reconstruction for extended circumferential pharyngo-laryngectomy: A case report.

Optimising combination therapy for paediatric, adolescent and young adult patients with non-rhabdomyosarcoma soft tissue sarcomas: The OCTOPUS platform trial.

Related Experiment Videos

Integrated therapeutic strategies for anaplastic thyroid carcinoma

Abstract:

Related Concept Videos

Related Articles